Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7437 in Advanced Solid Tumors
NCT07360314Phase 1Recruiting
- Sponsor
- EMD Serono
- Start
- Feb 2026
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of M7437 in solid tumor, sponsored by EMD Serono. Primary endpoints: Dose Limiting Toxicities at 21 days and Treatment-Emergent Adverse Events. Started Feb 2026; status: recruiting.
02
Drugs
M7437
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07360314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07360314.